Atlas Trials

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Clinical trial NCT05391750 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05391750
Sponsor
Emory University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Start date
2022-10-19
Primary completion
2027-02-12
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.